To date, the FDA has identified more than 40 patients who received infusions of the Wallcur simulated saline products after an alert was issued in early January. Many patients have reported experiencing fever, chills, tremors and headaches.
Since beginning the investigation, the FDA has reached out to other companies that market simulated products for training purposes to make them aware of this incident and ensure steps were taken to remedy any potentially confusing situations between training products and real drugs.
More articles on the FDA:
IBM lobbies Congress to ease FDA regulations on Watson
FDA provides clearance for Roche MRSA/SA test
FDA approves meningococcal disease vaccine
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
